MMP2 and Alzheimer disease: Compared to the control group, the RUNX1flox/flox group exhibited a significant reduction in MMP2 expression and a notable elevation in NF-κb and TNF-α expression within the PVAT at 4 weeks post establishment of AD (Fig. 1e).